Jazz Pharmaceuticals (JAZZN) Q3 2026 Earnings Report
MX:JAZZN Q3 2026 EPS Results
- Actual EPS
- -MXN 72.09
- Consensus EPS
- -MXN 74.92
- Beat/Miss
- Beat by +MXN 2.82
- One Year Ago EPS
- MXN 151.06
MX:JAZZN Q3 2026 Revenue Results
- Actual Revenue
- MXN 23.04B
- Expected Revenue
- MXN 22.45B
- Beat/Miss
- Beat by +MXN 590.00M
- YoY Revenue Growth
- +10.11%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/02/2026
- Time
- After Close
- Conference Call
- Monday, November 2, 2026
MX:JAZZN Upcoming Earnings
Jazz Pharmaceuticals's next earnings date is estimated for March 2, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:JAZZN Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was strongly positive. Jazz reported record revenue, raised full-year revenue and gross-margin guidance, delivered strong growth across oncology and Xywav, and described an encouraging early launch for Ziihera supported by favorable clinical data and market access. The company also highlighted substantial cash generation, pipeline progress and the Actio acquisition. Offsetting factors included lower adjusted gross margin, a reported non-GAAP loss driven by the Actio acquired IPR&D charge, a measured near-term Modeyso revenue pace, and future competitive pressure for Zepzelca. The positive operating and strategic developments significantly outweighed the stated challenges.
Company Guidance
For 2026, Jazz raised and narrowed total revenue guidance to a range of $4.775 billion to $4.85 billion, representing nearly 13% growth over 2025 at the midpoint; rare sleep revenue is now expected to be $2.125 billion to $2.175 billion, led by Xywav growth of low double digits to low teens, while non-GAAP gross margin guidance increased by 50 basis points to a range of 90.5% to 91.5%, non-GAAP effective tax rate guidance is a range of 19.5% to 21.5%, and share count guidance remains unchanged at 69 million to 70 million shares. Ziihera peak sales potential is a range of $3 billion to $5 billion, Modeyso has a $500 million peak expectation in the U.S., and Zepzelca is likely to face a future headwind in 2027.
- Record Quarterly Revenue and Raised GuidanceThird-quarter revenue reached a record $1.24 billion, up 10% year-over-year. The company raised and narrowed 2026 total revenue guidance to $4.775 billion to $4.85 billion, with the midpoint representing nearly 13% growth over 2025.
- Strong Oncology and Xywav GrowthThe oncology portfolio grew 35% year-over-year, while Xywav revenue increased 12%. Oncology growth was driven by the launches of Modeyso and Zepzelca in the first-line maintenance setting, and Xywav continued to show sustained demand.
- Ziihera Launch Gaining Early MomentumZiihera generated $21 million in third-quarter net product sales following its approval and launch in first-line HER2-positive metastatic GEA. New account ordering increased threefold in September compared with August, more than 80% of new ordering accounts came from community clinics, and average vial demand per selling day increased approximately 40% month-over-month.
- Ziihera Market Access and Prescriber AdoptionThe company reported smooth market access for Ziihera, supported by an existing permanent J-code and preferred NCCN guideline status. More than 3/4 of HCPs in early post-launch research reported a high likelihood to prescribe Ziihera for GEA; separately, 79% of surveyed oncologists reported high intent to prescribe it for first-line GEA. The company also reported frictionless reimbursement, positive formulary and EHR order-set inclusion, and strong pathway adoption.
- Ziihera Clinical Data Supports Expansion OpportunityIn the final HERIZON-GEA-01 analysis, Ziihera plus chemotherapy reduced the risk of death by 24% versus trastuzumab plus chemotherapy. Nearly 40% of patients receiving the triplet regimen versus 23% receiving trastuzumab plus chemotherapy were alive at three years, with median overall survival of 27 months. Longer follow-up showed an overall-survival hazard ratio of 0.65 for Ziihera plus tislelizumab and chemotherapy, and the company increased Ziihera peak-sales potential to $3 billion to $5 billion.
- Xywav Commercial Performance and Patient GrowthXywav net product sales increased 12% to $483 million, with approximately 425 net patient additions during the quarter and 17,550 active patients at quarter-end. The company said the low-sodium formulation continues to be valued by physicians, patients and payers, and that uptake of high-sodium generics has been limited.
- Xywav Clinical Differentiation and DurabilityUpdated DUET trial findings showed that Xywav consolidates disrupted nighttime sleep and reduces debilitating daytime symptoms in narcolepsy and idiopathic hypersomnia. A Xywav study also showed a clinically meaningful reduction in blood pressure for patients switching to the low-sodium formulation. The company expects Xywav to remain a foundational therapy across NT1, NT2 and idiopathic hypersomnia.
- Epidiolex Demand and Expansion PlansEpidiolex net product sales reached $295 million, supported by solid underlying demand. The FDA accepted the NDA for a new cannabidiol oral capsule formulation with a PDUFA date of April 16, 2027. Jazz is also advancing a developmental and epileptic encephalopathy trial and an ongoing focal-onset seizure trial.
- Zepzelca Growth in First-Line MaintenanceZepzelca net product sales increased 32% to $104 million, driven by adoption of the Zepzelca and atezolizumab combination in first-line maintenance small-cell lung cancer. The company said the regimen provides a new maintenance option and that Zepzelca remains an established and practical treatment option.
- Modeyso Has Reached Significant Commercial ScaleModeyso generated approximately $200 million in net product sales since its third-quarter 2025 launch, with approximately 725 patients treated as of the third quarter of 2026. Academic-center adoption remained strong, and the company is expanding into community oncology networks through peer-to-peer programs and initiatives to increase biomarker testing.
- Actio Acquisition Expands Rare-Epilepsy PipelineJazz completed its acquisition of Actio Biosciences during the quarter, adding ABS-1230, a precision therapy designed to selectively inhibit the KCNT1 ion channel. Early proof-of-concept trials demonstrated meaningful seizure reductions. ABS-1230 has received fast-track, rare pediatric disease and orphan drug designations and is advancing in the Phase Ib/II KYRON trial, which is structured as a registrational trial.
- Pipeline Milestones Advancing Across Oncology and SleepJazz initiated a Phase I first-in-human trial of JZP269, an orexin 2 receptor agonist. Zanidatamab development continues in metastatic and earlier-stage breast cancer, colorectal cancer and non-small-cell lung cancer. Zanidatamab also received FDA breakthrough therapy designation for previously treated HER2-positive colorectal cancer. The company expects ACTION trial top-line results in the first half of 2027 and EmpowHER-303 data in late 2027 or early 2028.
- Strong Cash Flow and Financial FlexibilityJazz generated $1.3 billion of operating cash flow during the first nine months of the year and ended the quarter with $2.9 billion of cash and investments. The company issued $1.25 billion in convertible notes, reduced the interest rate and extended the maturity of its term loan, and said it remains positioned to invest in marketed products, its pipeline and corporate development.
- Improved Gross-Margin GuidanceThe company increased its non-GAAP gross-margin guidance by 50 basis points to a range of 90.5% to 91.5%. Rare-sleep revenue guidance was raised to $2.125 billion to $2.175 billion, with Xywav growth expected to be in the low double digits to low teens.
- Commercial Leadership Achievements and Transition PlanningManagement credited the commercial organization with propelling Epidiolex to blockbuster status, executing key oncology launches and strengthening Jazz's leadership in sleep medicine. Chief Commercial Officer Samantha Pearce announced her retirement and will remain through the appointment of her successor to support a seamless transition.
- Rare-Disease Strategy and Regulatory SupportManagement highlighted the large unmet need in rare disease, noting that there are 30 million U.S. patients with rare diseases, approximately 10,000 rare diseases and no approved therapy for 95% of them. The company said the FDA's fit-for-purpose rare-disease framework and recent policy support for orphan-disease incentives are favorable developments for its strategy.
MX:JAZZN Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 02, 2027 | 2026 (Q4) | 130.44- | 123.38 | ― | ― |
| Nov 02, 2026 | 2026 (Q3) | -74.92-72.09 | 151.06 | -147.72% (-223.16) | |
| Aug 03, 2026 | 2026 (Q2) | 114.74106.10 | -153.29 | 169.21% (+259.39) | |
| May 05, 2026 | 2026 (Q1) | 86.23117.80 | 31.22 | 277.38% (+86.59) | |
| Feb 24, 2026 | 2025 (Q4) | 121.11123.38 | 122.63 | 0.61% (+0.74) | |
| Nov 05, 2025 | 2025 (Q3) | 110.48151.06 | 122.82 | 23.00% (+28.24) | |
| Aug 05, 2025 | 2025 (Q2) | -141.33-153.29 | 98.48 | -255.66% (-251.77) | |
| May 06, 2025 | 2025 (Q1) | 86.5531.22 | 49.8 | -37.31% (-18.58) | |
| Feb 25, 2025 | 2024 (Q4) | 108.92122.63 | 93.28 | 31.47% (+29.36) | |
| Nov 06, 2024 | 2024 (Q3) | 102.16122.82 | 89.93 | 36.57% (+32.89) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
